Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › SLDB

Solid Biosciences

SLDB Rare disease Lead: Phase 3 5 Biotech Distilled articles ↓ 29 filings & releases ↓ Cash $126M (Sep 30, 2026) ↓ 5 verdicts ↓ 2 timing quotes ↓
CardiovascularNeurology Gene Therapy

Market cap $736M 111.6M shares (10-Q, Oct 30, 2026) × $6.59 close Nov 6, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. SGT-501 Ph1 start2H 2026SGT-501 Ph1 start, 2H 2026, routine
  2. IMPACT DUCHENNE Phase 3 corporate2H 2026IMPACT DUCHENNE Phase 3 corporate, 2H 2026, routine
  3. SGT-003 FDA feedbacklate 4Q 2026SGT-003 FDA feedback, late 4Q 2026, thesis-defining
  4. SGT-501 Ph1 readout1H 2027SGT-501 Ph1 readout, 1H 2027, notable
  5. SGT-212 Ph1 readout1Q 2027SGT-212 Ph1 readout, 1Q 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

POLARIS-101

Next-generation, rationally engineered muscle-tropic AAV capsid (formerly AAV-SLB101) designed for enhanced skeletal and cardiac muscle tropism and reduced liver biodistribution; used as delivery capsid for SGT-003 in Duchenne muscular dystrophy; licensed to corporations, institutions and academic labs

Targets: integrin receptors

Novel Capsid and Promoter Libraries

Scalable high-throughput platform for next-generation capsid design targeting cardiac and neuromuscular diseases; leverages deep capsid structure knowledge, peptide insertions, generative AI, and affinity maturation to improve biodistribution and expression. Capsid selection from first library anticipated 2H 2026.

Mayo Clinic Cardiac Gene Therapy Collaboration · Mayo Foundation for Medical Education and Research

Collaboration platform with Mayo Foundation for Medical Education and Research covering six undisclosed preclinical cardiac gene therapy programs; Mayo conducts IND-enabling studies, Solid retains rights to select programs for clinical development and exclusive commercialization.

POLARIS-101 · Addgene

Next-generation, muscle-tropic AAV capsid (formerly AAV-SLB101) designed to target integrin receptors, with enhanced cardiac and skeletal muscle transduction and decreased liver targeting; used in SGT-003 and licensed broadly to corporations, institutions, and academic labs.

Capital (as filed)

Cash
$126M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$223M Sep 30, 2026
Operating cash flow
−$45.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$378M cash, runway mid-2028 per the update of Aug 6, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Solid Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-03-12 Watch Solid Biosciences (SLDB) - Scientific Deep Dive for SGT-003 and Pipeline Products Compelling second-mover with elegant nNOS-recruiting transgene and clean safety profile, but thesis hinges on a binary H1 2026 FDA accelerated approval pathway decision.
  2. 2026-03-22 Hold UPDATE: Solid Biosciences (SLDB) - The S-3 Dilution Playbook, a New 13D, and the Burn Rate Reality S-3 shelf filing signals near-term dilution pressure but a Schedule 13D from an active institutional filer provides a floor and validates M&A appeal; use post-S-3 volatility to scale in ahead of H1 2026 FDA meeting.
  3. 2026-05-12 Hold speculative UPDATE: Solid Biosciences (SLDB) - The Dilution Gap Closes, the Phase 3 Clock Starts Dilution gap closed at favorable price with runway extended to H1 2028, Phase 3 now dosing, and CMC de-risked via FDA potency assay alignment — downside of an unfavorable FDA outcome is now materially smaller.
  4. 2026-06-25 Hold UPDATE: Solid Biosciences (SLDB) - RA Capital Doubles Down, and the ATM Quietly Fires RA Capital identified as the 13D filer and adding aggressively into the FDA binary at above-placement prices, reinforcing institutional conviction; thesis unchanged with ATM providing ongoing dilution drip but at prices well above the March raise.
  5. 2026-08-07 Speculative buy speculative UPDATE: Solid Biosciences (SLDB) - The Binary Slips to Q4, and the ATM Gets a Bigger Barrel FDA accelerated approval meeting slipped to Q4 2026, share count up 36% YTD via ATM, and a second resolved SAE emerged, but cash runway, Phase 3 dosing, and core nNOS/DAPC science remain intact — patient investors may wait for ATM to clear before adding.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (29)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 1, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

14 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)